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ABSTRACT
The indubitable existence of a graft-versus-lymphoma (GVL) effect is difficult to prove directly. This article
reviews the difficulties in interpreting the current literature in this field and, with a number of caveats, argues
for the existence of a clinically meaningful GVL effect in follicular, mantle cell, small lymphocytic, and Hodgkin
lymphomas. The evidence, however, for a potent GVL effect in diffuse large-cell lymphoma and Burkitt
lymphoma is not convincing. Policies for allografting in lymphoma are proposed on the basis of this evidence.
The immunobiology of GVL effects is discussed—in particular, the expression of HLA class I and II and
co-stimulatory molecules on lymphomas that influence the generation of alloreactive T cells—together with
future directions in immunotherapy that may help to eradicate chemoresistant disease.
© 2004 American Society for Blood and Marrow Transplantation
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DNTRODUCTION
The recognition that the incidence of relapse after
utografting for recurrent or refractory lymphoma is
sually substantial and the emerging use of reduced-
ntensity (RI) allogeneic conditioning regimens have
esulted in the need to evaluate critically which lym-
homas are amenable to graft-versus-lymphoma
GVL) effects.
A GVL effect can be convincingly demonstrated
nly by the durable resolution of biopsy-proven resid-
al progressive disease after allografting in response to
mmunomodulation such as withdrawal of immuno-
uppression or donor leukocyte infusion (DLI). Indi-
ect evidence may include eradication of active disease
y minimally cytotoxic conditioning regimens and al-
ogeneic cell infusion and statistical association be-
ween graft-versus-host disease (GVHD) with a lower
isk of relapse and T-cell depletion with a higher risk
f relapse. Although a substantial reduction in relapse
ith a plateau in disease-free survival (DFS) after
llogeneic versus autologous transplantation in com-
arable patient groups would also be consistent with a
VL effect, the possible contribution of reinfused t
B&MTutologous tumor cells to relapse [1] means that such
bservations are not deﬁnitive proof.
A number of comprehensive reviews of single-
nstitution and registry studies of allografting in lym-
homa with both myeloablative and RI conditioning
egimens have been published [2,3]. The purpose of
his article is not to revisit the literature in detail, but
o review the difﬁculties in assessing this literature, to
ritically evaluate the evidence for a GVL effect in
peciﬁc histologic subtypes of lymphoma by using the
riteria described previously, and to propose allograft
olicies based on this review. The proposed allograft
olicies, representing our unit’s current policies, are
ubject to much debate but provide a framework for
iscussion. Finally, we discuss the biological charac-
eristics of lymphoma cells and their environment,
hich may affect their immunologic responsiveness,
nd we speculate on future directions in harnessing
VL effects to eradicate chemoresistant disease.
IFFICULTIES IN ASSESSING THE LITERATURE
There are a number of difﬁculties in interpreting
he literature on GVL effects.
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5. Registry analyses.
(i). Many have incorporated a number of lym-
phoma subtypes with distinct histopathologic,
molecular, and clinical characteristics into a
single group for the purposes of analysis of
GVL effects, making it difﬁcult to evaluate
responses in speciﬁc entities. For example,
diffuse small cleaved (often mantle cell
[MCL]) and follicular large-cell lymphomas
have been regarded by the European Bone
Marrow Transplant (EBMT) registry as in-
termediate-grade lymphomas under the
Working Formulation and analyzed together
[4], whereas another transplant analysis from
this group classiﬁed patients as having only
low- or high-grade lymphoma [5]. In addi-
tion, many of these registry reviews include
patients undergoing different conditioning
regimens and GVHD prophylaxis.
(ii). Lack of centralized histologic review, so that
the reported diagnoses have not been inde-
pendently veriﬁed.
(iii). Probable imbalances in baseline pretransplan-
tation characteristics in studies comparing the
outcome of autografts versus allografts [4],
together with potential variability in patient
selection and standards of supportive care
over long periods of analysis.
(iv). Not surprisingly, the results of these studies
are often inconsistent.
. Retrospective single-institution studies comparing
autografts with allografts are subject to various po-
tential confounding factors, such as referral bias,
physician preference, and improvements in out-
come over time, such that deﬁnitive conclusions
are rarely possible.
. There are substantial differences in the intensity of RI
conditioning regimens. Fludarabine/melphalan 140
to 180 mg/m2, for example, may well be myeloabla-
tive, because chimerism early after transplantation is
usually exclusively donor and because the risk of
GVHD is comparable to that with traditional my-
eloablative regimens [6]. In contrast, ﬂudarabine/low-
dose cyclophosphamide is clearly not ablative, gener-
ally results in mixed chimerism, and has a relatively
low incidence of GVHD [7]. Moreover, most RI
conditioning studies from single institutions or reg-
istries have short-term follow-up, so the durability of
responses is not established.
. The importance of documentation by biopsy of viable
residual disease after transplantation in assessing the
response to DLI or withdrawal of immunosuppres-
sion is particularly relevant because functional imag-
ing with positron emission tomography or gallium
scanning may not always reliably distinguish inﬂam-
matory from neoplastic tissue or indolent from ag-
gressive lymphoma, which may coexist. l
80. Although responses to DLI have been well docu-
mented in some lymphomas, particularly follicular
and MCLs, this does not necessarily mean that all
such lymphomas are immunologically responsive.
Some cases have documented a GVL effect in re-
sponse to DLI that seems to alter the natural his-
tory of previously progressive lymphoma but that is
not durable, suggesting that malignant clones may
differ in their susceptibility to immunotherapy.
VL EFFECTS IN HISTOLOGIC SUBTYPES AND
ROPOSED ALLOGRAFT POLICIES
Data for each subtype will be discussed as follows:
1) DLI, (2) single-institution and registry reviews of
I transplants, and (3) institution and registry reviews
f myeloablative transplants, including, where avail-
ble, an evaluation of the effect of GVHD on relapse.
ollicular Lymphoma
A graft-versus–follicular lymphoma (FL) effect
as suggested by case reports of resolution of active
isease by DLI [8,9] and was conﬁrmed more recently
n a British survey in which 8 of 13 patients with overt
L after allografting achieved complete remission
CR) after DLI [10]. A high rate of remission after RI
onditioning has been reported [7], although most
atients had nonbulky chemosensitive disease at trans-
lantation and although follow-up was relatively short
n a disease with a propensity for late relapse. An
BMT registry analysis of RI allografts in low-grade
ymphoma (Working Formulation) using a variety of
onditioning regimens in heavily pretreated patients,
ost with chemosensitive disease and with sibling
onors, demonstrated a 1-year probability of disease
rogression of 21% and 2-year progression-free sur-
ival (PFS) of 54%; pretransplantation chemosensitiv-
ty was the only signiﬁcant factor predicting for pro-
ression [5]. No relapses were seen beyond 1 year,
lthough few patients were followed up beyond 2
ears. There are minimal data on the outcome after
nrelated donor transplantations for FL and other
ymphomas [4,5,11,12].
Single-institution studies with long-term follow-up
ave reported a low incidence of relapse after myeloab-
ative allografts for refractory or recurrent indolent non-
odgkin lymphoma (NHL), predominantly follicular
13,14], which seems less than after autografts [15]; this
s consistent with an EBMT registry analysis [4]. Re-
ently the International Bone Marrow Transplant Reg-
stry (IBMTR) and the Autologous Bone Marrow
ransplant Registry, in a retrospective study, compared
he outcome of myeloablative allogeneic versus purged
utologous versus unpurged autologous transplants [16].
llografts had a higher treatment-related mortality and a
ower risk of recurrence. Few recurrences occurred after
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Graft-versus-Lymphoma-Effects
Byears, although the maximum follow-up of 5 years is
till relatively short. Intriguingly, the relapse rate was
igher in unpurged versus purged autografts, and there
as no association between acute or chronic GVHD and
ecurrence. The EBMT registry analysis also found no
ffect of acute GVHDon relapse, although in the British
eview, the responses of FL to DLI correlated with both
cute and chronic GVHD [10].
Overall, these data suggest that the major beneﬁt of
llografting in FL may relate to effective high-dose che-
oradiotherapy followed by infusion of uncontaminated
tem cells rather than a GVL effect. The absence of a
igniﬁcant difference in relapse risk after syngeneic ver-
us allografts for FL and the reduction in recurrence rate
fter syngeneic versus autologous unpurged transplanta-
ion is consistent with this [17], although a syngeneic
VL effect cannot be excluded. To complicate the issue,
owever, a prospective randomized autograft study
ound no beneﬁt in PFS or overall survival between
urged and unpurged marrow [18].
Long-term results of minimally cytotoxic condi-
ioning regimens in patients with active disease are
eeded to clearly evaluate the clinical effect of a graft-
ersus-FL effect. Additional questions include the du-
ability of responses after RI allografts, the effect of
he histologic grade in FL on the incidence of relapse,
he outcome after unrelated donor allografts, and the
dentiﬁcation of tumor antigens that are immunolog-
cally relevant for allogeneic responses.
Because of a relatively high risk of both early and late
elapse after autografting, in general an allograft is the
ransplant option recommended if a compatible sibling is
vailable. We consider patients up to age 60 to 65 years,
epending on their general ﬁtness and level of donor
ompatibility. A well-matched unrelated donor trans-
lant is considered in selected younger patients, gener-
lly younger than 45 years and with a good performance
tatus. The indications for transplantation are at least 1
f (1) progressive symptomatic disease within a year of
HOP-like (cyclophosphamide, hydroxydaunomycin,
incristine, and prednisone) or purine analog–based
herapy either as induction or for relapse or (2) multiply
elapsed disease.
Our preference is to attain a minimal residual
isease state (usually with ﬂudarabine with or without
yclophosphamide with or without rituximab, de-
ending on prior therapy), and we use a very-low-
ntensity conditioning regimen such as ﬂudarabine/
ow-dose cyclophosphamide or ﬂudarabine/low-dose
otal body irradiation [12], with the addition of ritux-
mab if not used previously [7]. This is based on our
cceptance that a graft-versus-FL effect exists to a
egree. The intention is to achieve mixed chimerism
arly after transplantation to reduce the risk of severe
cute GVHD and to gradually convert to donor chi-
erism either from the natural course of the trans-
lantation or with DLI. More intensive conditioning c
B&MTith increased organ toxicity and a higher risk of
VHD due to early establishment of full donor chi-
erism (ﬂudarabine/melphalan or cyclophosphamide/
otal body irradiation) is reserved for patients with
ulky, aggressive, or chemorefractory disease.
antle Cell Lymphoma
The role of allografting in MCL has been re-
iewed by Sweetenham [19]. A graft-versus-MCL ef-
ect has been unequivocally documented in case re-
orts of resolution of progressive disease after
ithdrawal of immunosuppression [20,21] or DLI
22]. This is broadly consistent with single-institution
tudies reporting a low relapse rate after RI [23] and
yeloablative [21] conditioning for advanced or re-
urrent chemosensitive disease, although the fol-
ow-up in both of these studies was relatively short.
his contrasts with a poor outcome in an EBMT
egistry survey in 22 older patients undergoing RI
llografts [5]: this was due to a high early transplant-
elated mortality and a substantial rate of relapse. The
bility of a GVL effect to eradicate chemoresistant
CL or to improve the poor outcome observed in
atients autografted in CR1 with high 2-microglobu-
in [24] is not proven. Moreover, although a GVL
ffect may occur in the diffuse form of the disease [21],
ts activity against the more aggressive blastoid variant
s not known. The effect of GVHD on relapse in
CL has not, to our knowledge, been evaluated.
Although there is some conﬂicting evidence, we
elieve that an allograft is appropriate therapy for
atients with relapsed MCL, because the autograft
esults with readily available conditioning regimens
re poor [25]. The intensity of conditioning used de-
ends on disease status and on patient age and perfor-
ance status. Ideally, the allograft should be offered
n ﬁrst relapse rather than subsequent relapses and
imited to patients with chemosensitive disease. The
ptimal approach to patients in CR1 is controversial.
ptions include an autograft [26] or observation, the
atter based on promising results with short-term fol-
ow-up in patients receiving aggressive induction ther-
py, including rituximab, without an autograft [27].
his has to be balanced against the strong evidence
or an allogeneic graft–versus-MCL effect. Currently
ur preferred option is a very-low-intensity allograft
n CR1 in patients younger than 60 years with a
ibling donor, particularly in those with increased 2-
icroglobulin at diagnosis. A randomized study ad-
ressing observation versus autograft versus RI allo-
raft in CR1 is needed.
hronic Lymphocytic Leukemia/Small
ymphocytic Lymphoma
A durable response to DLI has been reported in
hronic lymphocytic leukemia (CLL) [28], although
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5ritish data suggest that the response may be less
requent than in FL [10]. Promising early results of RI
onditioning allografts have been reported by the
BMT registry [29] and Schetelig et al. [30]. The
ormer study reported a 2-year probability of relapse
f 31%, with no relapses beyond 12 months in pa-
ients receiving T cell–replete grafts, contrasting with
ngoing late relapses in those receiving T cell–de-
leted grafts. The development of chronic GVHD
as very signiﬁcantly associated with a lower risk of
elapse. In the latter study, a graft-versus-CLL effect
as suggested by the late occurrence of remissions and
he effectiveness of DLI in early relapse; DLI was
neffective in patients with a high tumor burden. Also
onsistent with, but not proof of, a graft-versus-CLL
ffect are registry data suggesting a lower relapse rate
fter allografts than autografts, with a plateau in DFS
fter allografting [31].
Our policy is similar to that with FL. Grafting is
ffered to suitable patients with disease relapsing early
fter, or refractory to, purine analog–based therapy.
he intensity of conditioning depends on the chemo-
ensitivity and bulk of disease before transplantation.
odgkin Lymphoma
The largest series documenting the response to
LI for Hodgkin lymphoma (HL) relapsing after an
llograft has been reported recently [32]. Of 7 patients
ith progressive (n  6) or residual (n  1) disease
ho received DLI in the absence of chemotherapy, 3
chieved a CR, 2 of whom remained in remission with
ollow-up more than 12 months (K. Peggs, personal
ommunication). No response was seen in 2 patients,
nd a partial remission was seen in the other 2. Re-
ponses correlated with the development of GVHD.
f note, most patients had nodular sclerosing histol-
gy, had undergone a prior autograft, had disease that
ad run a relatively indolent course over a number of
ears, and did not have a rapidly progressive recent
elapse (K. Peggs, personal communication). Updated
ata from this group, reported in abstract form, are
onsistent with a response rate in approximately half
f this selected patient cohort [33]. Responses with
nd without GVHD after DLI have been reported by
ther authors, but concomitant chemotherapy, ab-
ence of histologic detail, and only short-term fol-
ow-up make these data difﬁcult to interpret [34,35].
Longer follow-up of various recently published
ingle-institution and registry series of RI condition-
ng allografts [36-38] may provide useful information.
he results of the largest of these studies, published in
bstract form [37], argue against the existence of a
rofound graft-versus-HL effect, because the out-
ome was poor in chemoresistant disease and there
as no plateau in PFS in the second year after trans-
lantation. A smaller single-institution study demon- s
82trated little effectiveness of this approach in patients
ith rapidly progressive disease relapsing early after
utografting [39]. Another study used ﬂudarabine/
ow-dose cyclophosphamide followed by DLI or pe-
ipheral blood stem cells in 8 patients with HL relaps-
ng after autografting [36]; 5 did not respond, 2 died of
cute GVHD, and only 1 patient was alive in CR,
otably, without evidence of donor engraftment.
Results of myeloablative allografts for HL are dis-
ppointing. The IBMTR reported a 3-year probabil-
ty of relapse of 65% and a DFS rate of 15% in 100
atients with advanced HL undergoing sibling allo-
rafts [40]. There are conﬂicting data about the effect
f GVHD on relapse and whether allografts have a
ower rate of relapse than autografts. A trend for a
ower probability of relapse after allografting com-
ared with autografting in patients with chemosensi-
ive disease has been reported [41]. An early EBMT
egistry analysis found a signiﬁcantly lower risk of
elapse with acute GVHD grade II or higher [42]. A
ore recent EBMT analysis, however, reported no
nﬂuence of acute GVHD on the rate of relapse and in
act reported a higher risk of relapse after allografts
ersus autografts for HL, although the former group
lmost certainly contained a higher proportion of pa-
ients with advanced chemoresistant disease [6].
A collaborative international effort is under way
mong various investigators examining the outcome
f patients undergoing RI allografts for HL relapsing
fter autografts. The effect of factors such as histology
classic versus lymphocyte predominant; the latter
linically behaves as a low-grade B-cell lymphoma and
s likely to be immunologically responsive), different
onditioning regimens, and acute and chronic GVHD
n relapse and survival will be examined in addition to
LI/withdrawal of immunosuppression in biopsy-
roven active disease. Prospective studies under con-
ideration include an autograft followed by an RI
llograft in poor-prognosis patients, the feasibility of
hich has been established [43].
An allograft for classic histology is considered only
f all of the following conditions apply:
. Biopsy-proven relapsed disease after autografting
in which the duration of remission after autograft-
ing is 6 months.
. The relapse is not rapidly progressive, is not che-
mosensitive, is not amenable to local radiotherapy
(eg, pulmonary relapse), and is preferably not as-
sociated with “B” symptoms.
. A second autograft is not feasible (eg, insufﬁcient
stem cells) [44].
The choice of conditioning regimen and whether
o consider an unrelated donor depends on factors
uch as patient age, time since previous high-dose
herapy, organ function, and degree of donor match.
deally, these patients should be enrolled on a pro-
pective study (see below).
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Biffuse Large-Cell Lymphoma
To our knowledge, there is no published system-
tic review of the role of DLI in diffuse large-cell
ymphoma (DLCL). There are only 2 reports of a
urable response to DLI after allografting: 1 in a
atient with relapsed mediastinal B-cell NHL [2] and
he other with Richter transformation of CLL [45]. A
emission lasting 140 days after cessation of tacroli-
us for relapsed T cell–rich B-cell NHL has been
eported; 3 other patients with relapsed DLCL did
ot respond to withdrawal of cyclosporine and DLI
46]. Failure of DLI despite GVHD has been docu-
ented in anaplastic large-cell NHL [47] and in lym-
homatoid granulomatosis and B-cell DLCL [48].
wo patients with high-grade NHL relapsing after a
onmyeloablative allograft did not respond to DLI
35].
Single-institution and registry data in this area are
ifﬁcult to interpret for the reasons outlined previ-
usly. Of note, many RI conditioning studies have
een published as abstracts only (without peer review).
ost studies have varied with respect to histology,
tatus at transplantation, and T-cell depletion. The
BMT registry reported the results of RI condition-
ng regimens (mainly ﬂudarabine based and varying
rom low-dose cyclophosphamide to high-dose mel-
halan) in 62 patients with high-grade lymphoma,
ncluding transformed low-grade disease [7]. The re-
ults were disappointing despite most patients having
hemosensitive disease before transplantation: the
robability of disease progression at 2 years was 79%,
ith a PFS of 13%.
The myeloablative allograft data are inconclusive.
here were no survivors in a series of 14 patients who
eceived allografts with a myeloablative regimen for
dvanced intermediate-grade NHL (predominantly
LCL) reported by the M.D. Anderson group in the
id 1990s; all died of progression or toxicity [49]. A
rench review found no effect of acute or chronic
VHD (although the data were not provided) in a
eries of allografts for aggressive NHL, predomi-
antly DLCL [50]. In this series, the 5-year survival
as 23% in 48 patients not in CR at transplantation—
esults not obviously different from those of autograft-
ng in a similar patient group.
A more recent survey from the EBMT registry
eported a lower relapse rate after myeloablative al-
ografting compared with autografting for intermedi-
te-grade NHL by using the Working Formulation
6]. As discussed previously, this category includes
ollicular large-cell, diffuse large-cell, and diffuse
mall cleaved (most likely mantle cell) histologies, so
he speciﬁc GVL effects in these individual histologies
annot be elucidated. Acute GVHD was associated
ith a reduced rate of relapse, but insufﬁcient data
ere available to analyze the effect of chronic GVHD. t
B&MTn contrast, the recent review by Bierman et al. [17]
howed no difference in relapse rate for intermediate-
r high-grade NHL between syngeneic, allogeneic T
ell–replete or–depleted, or autologous transplants,
lthough the mix of histologies, imbalances in pre-
ransplantation characteristics, and small numbers
particularly in the syngeneic and T cell–depleted
roups) make interpretation of these results difﬁcult.
There are few speciﬁc data on the outcome of
llografting for peripheral T-cell lymphomas. The
ilan group have reported in abstract form the out-
ome of RI conditioning in 8 patients with relapsed
odal peripheral T-cell lymphomas, most with che-
orefractory disease and in half of whom a previous
utograft had failed [51]. With a short median fol-
ow-up of 18 months, all were alive and in remission.
Questions that need to be addressed in properly
esigned studies include the effect of immunopheno-
ype (B versus T cell), histology (de novo B-cell
LCL versus follicular large cell versus transformed
ow grade), and location (nodal versus site speciﬁc, eg,
ediastinal or bony) on the outcome after transplan-
ation.
We are not convinced that a clinically relevant
raft-versus–de novo B-cell DLCL effect commonly
xists. Hence, an allograft is not generally offered to
atients with primary refractory disease, chemorefrac-
ory relapse, or postautograft relapse. Possible excep-
ions include those with transformed low-grade NHL
based hypothetically on a higher chance of a GVL
ffect in the presence of an underlying low-grade
omponent) relapsing more than 6 months after au-
ografting without rapid disease progression or medi-
stinal lymphoma [2]. An allograft is also considered
n patients with chemosensitive ﬁrst relapse in whom
ufﬁcient autologous stem cells cannot be collected or
n whom the collection is overtly contaminated with
ymphoma. Rituximab is offered after allografting to
atients with CD20 B-cell tumors who have not
reviously received this drug, on the basis of promis-
ng preliminary experience with this approach [52].
ymphoblastic Lymphoma
A single report of late-onset cutaneous relapse of
-cell lymphoblastic lymphoma (LBL) that re-
ponded durably to withdrawal of cyclosporine and a
are of cutaneous GVHD has been published [46]. A
ecent publication from the IBMTR and the Autolo-
ous Bone Marrow Transplant Registry compared
utologous versus myeloablative non–T cell–depleted
llografts for LBL [53]. The relapse rate beyond 6
onths after transplantation was signiﬁcantly lower in
he allograft patients and was independent of disease
tatus at the time of transplantation. A graft-versus-
BL effect cannot be concluded unequivocally from
hese data, however, because infusion of contaminated
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5utologous cells may have contributed to a higher risk
f relapse. GVHD had no signiﬁcant effect on the risk
f relapse, but the study was not powered adequately
o detect a small effect. EBMT studies have also dem-
nstrated a lower risk after allografting for LBL and
uggested a reduced risk with acute [6] and chronic
54] GVHD.
A myeloablative allograft is offered to suitable
atients with high-risk LBL in CR1 or those with
hemosensitive relapse. Immunosuppression is ta-
ered early in the absence of GVHD [55].
urkitt Lymphoma
There is a paucity of data in this area and no
onvincing evidence that allografting can cure adult
atients with Burkitt lymphoma relapsing after, or
efractory to, intensive induction regimens. A re-
ponse to withdrawal of immunosuppression has been
eported, but this was not durable [56]. The M.D.
nderson group reported the results of myeloablative
llografts in 10 patients with diffuse small noncleaved
ymphoma and noted a very high rate of rapid disease
rogression after transplantation [49]. No difference
n relapse rate between autologous and allogeneic
ransplants for Burkitt lymphoma and no effect of
cute GVHD on the rate of relapse have been re-
orted by the EBMT [6].
Allografts are not offered to patients with Burkitt
ymphoma, because most patients are either cured by
ggressive induction regimens [57] or relapse early
ith rapidly progressive chemoresistant disease.
utaneous T-Cell NHL
A graft-versus–mycosis fungoides effect has been
eported by a number of investigators. In one case,
istologically and molecularly documented persistent
isease at day 60 after a nonmyeloablative allograft
able 1. Lymphoma Type and Evidence for GVL Effect
Lymphoma Type
Durable* Response to
DLI/Withdrawal of IS
Durab
Very-Lo
Con
ollicular Yes
antle cell Yes
LL/diffuse small cell Yes
odular sclerosing Hodgkin Yes† P
iffuse large B cell Yes† P
ymphoblastic Yes†
urkitt No
ycosis fungoides Yes
E indicates not evaluable, ie, insufﬁcient data or duration of follow
immunosuppression.
In most of the studies, follow-up was less than 2 or 3 years.
See text for caveats.
Studies have not shown a reduction in relapse.egressed after withdrawal of cyclosporine and devel- t
84pment of cutaneous GVHD. Remission was main-
ained for 24 months of follow-up [58]. In a second
ase, mycosis fungoides recurring 9 months after a
yeloablative allograft subsequently resolved after
essation of cyclosporine and development of lichen-
id chronic GVHD. However, low-grade cutaneous
isease subsequently recurred over the next 4 years
nd responded temporarily to DLI [59]. The latter
ase points out the necessity of long-term follow-up in
valuating GVL effects. We have observed a patient
ith large-cell transformation of mycosis fungoides in
hom the low-grade cutaneous disease regressed with
he onset of chronic GVHD but in whom the large-
ell component progressed.
Resolution after withdrawal of immunosuppres-
ion of a cutaneous CD30 large T-cell lymphoma
ersisting after a nonmyeloablative allograft has been
eported [60]. A GVL effect was suggested by inﬁl-
ration of the skin tumors by donor lymphocytes.
Suitable patients with relapsed mycosis fungoides
re considered for an allograft. Large-cell transforma-
ion is a contraindication.
ummary
Table 1 summarizes, to the best of our knowledge,
ach of the GVL criteria for various types of lym-
homa. There are insufﬁcient data to comment mean-
ngfully for histologies such as peripheral T-cell
HL, hepatosplenic lymphoma, and nodular lympho-
yte-predominant HL.
A number of collaborative groups have phase II
rials under way evaluating the role of RI conditioning
egimens in diseases such as HL, in which the exis-
ence of a GVL effect is controversial. Enrollment of
atients in these prospective studies is strongly en-
ouraged because without a collaborative systemic ap-
roach in a large number of patients, it is unlikely that
ponse to
-Intensity
g Allo
Less Relapse with
GVHD and/or
More Relapse with
T-Cell Depletion
Plateau on DFS Curve after
Allo and/or Less Relapse
with Allo versus Auto
† No†‡ Yes
† NE NE
Yes Yes
no Conflicting data Conflicting data
no NE No
Conflicting data Yes
NE No
NE NE
lo, allogeneic transplantation; Auto, autologous transplantation; IS,le* Res
w-Dose
ditionin
Yes
Yes
Yes
robably
robably
NE
NE
NE
-up; Alhe questions raised in this article will be answered.
U
q
G
b
T
w
e
T
v
e
a
e
G
s
m
l
l
v
a
t
d
A
o
G
m
i
t
e
a
s
t
B
r
a
a
t
c
b
s
w
T
B
n
d
i
d
[
t
i
e
i
a
c
n
v
m
t
l
s
e
T
o
i
d
t
i
F
n
p
s
s
e
i
s
e
e
C
c
t
a
a
B
t
a
a
d
p
r
C
t
W
t
C
v
[
s
T
t
Graft-versus-Lymphoma-Effects
Bltimately, however, randomized trials will be re-
uired for deﬁnitive conclusions.
VL IMMUNOBIOLOGY
In the following section, we review the immuno-
iology of B cells as both initiators and targets of
-cell cytotoxicity. By examining the mechanisms by
hich malignant B cells may be induced to function as
ffective antigen-presenting cells (APC) to allogeneic
cells, we may better understand (1) the observed
ariations in sensitivity of lymphoma subtypes to GVL
ffects and (2) how to successfully manipulate inter-
ctions between T cells and lymphoma to maximize
radication of residual disease while minimizing
VHD.
The induction of a GVL effect after allogeneic
tem cell transplantation (SCT) is dependent on tu-
or-antigen recognition, subsequent cytotoxic T
ymphocyte (CTL) generation, and sensitivity of the
ymphoma to cytotoxicity effector mechanisms. Acti-
ation of resting donor T cells follows recognition of
lloantigens or tumor-speciﬁc antigens expressed on
he surface of either professional APCs, such as den-
ritic cells (DC), or lymphoma cells themselves. Host
PCs are central to donor T-cell activation, as dem-
nstrated in animal models in which GVHD and
VL effects diminish and are eventually lost as initial
ixed APC chimerism evolves to full donor chimer-
sm [61-63]. Once activated, CTLs mediate the effec-
or phase of GVHD/GVL via cytotoxicity produced
ither by cell/cell contact mechanisms (Fas, perforin,
nd tumor necrosis factor-) or by the production of
oluble mediators, including interferon- and soluble
umor necrosis factor- [64].
-Cell Lymphoma
The question arises whether B lymphoma cells
epresent competent APCs for direct activation of
lloresponsive T cells or whether B lymphoma cells
re subsequent targets for CTLs generated initially by
he allostimulatory effects of host DCs. Normal B
ells constitutively express both major histocompati-
ility complex (MHC) class I and II, along with co-
timulatory molecules, including CD80 and CD86,
hich are essential for generation of CTLs from naive
cells.
It is important to note that the activation status of
cells is central to their ability to act as APCs. Resting
ormal B cells have been variously shown to induce
irect tolerance of antigen-speciﬁc CD8 T cells [65],
nduce T-cell anergy via TGF- production [66],
ownregulate interleukin-12 production by DCs
67,68], and inﬂuence T-helper type 1 and 2 differen-
iation via the production of regulatory cytokines,
ncluding interleukin-10 [69]. Similarly, resting B cells v
B&MTxert a regulatory function in in vivo models of T-cell
mmunity, including tumor rejection [70,71].
Conversely, B cells activated via ligation of CD40
re potent inducers of T-cell activation, which in turn
an deliver antitumor immune responses against both
on–B-cell [72] and B-cell [73-75] malignancies in
ivo. The expression of co-stimulatory surface-bound
olecules is signiﬁcantly enhanced after B-cell activa-
ion by a range of stimuli, including CD40L and
ipopolysaccharide [76]. B cells activated by lipopoly-
accharide and interleukin-4, however, fail to induce
ffector T-cell responses [75], and this may lead to
-cell tolerance [66], thus underlining the importance
f the different outcomes of B-cell activation depend-
ng on the stimulating signal used. These studies in-
icate that normal B cells can potentially be induced
o act as effective APCs for the generation of T-cell
mmune responses.
ollicular Small-Cell Lymphoma and MCL
Parallel to ﬁndings in normal B cells, some malig-
ant lymphoma cells may also demonstrate an APC
henotype. B cells isolated from follicular NHL and
mall lymphocytic lymphoma/CLL share phenotypic
imilarities to normal resting B cells in both their
xpression of MHC and co-stimulatory molecules and
n their responses to CD40L. These lymphomas con-
istently show high levels of CD80, CD86, and CD40
xpression [77,78]. Similarly, the B cells from MCL
xpress CD40 and show intense upregulation of
D80 and CD86 after treatment with CD40L [79].
The sensitivity of small-cell lymphomas to T-cell
ytotoxicity has been demonstrated by studies of au-
ologous vaccination with either DCs [80,81] or killed
utologous lymphoma cells [82]. In these studies of
utologous immunotherapy, CTL generation against
-cell idiotype was successfully achieved from within
he patient’s naive-T-cell population. In the post–
llogeneic SCT setting, there is potential not only for
greater range of CTLs to be generated from the
onor T-cell repertoire, but also for residual lym-
homa B cells to act as functional APCs. Activation of
esting lymphoma B cells may occur in response to
D40L provided by donor CD4 T cells alloreactive
o host major or minor histocompatibility antigens.
hen activated by CD40L, the lymphoma B cells, in
urn, can drive the subsequent activation of allogeneic
D8 T cells to CTLs. Once generated, both acti-
ated CD8 T cells [83] and subsets of CD4 T cells
84] are capable of inducing the cytotoxicity of the
timulatory APCs and eradicating residual disease.
his hypothesis is supported by the observation that
hese lymphoma subtypes are those that show con-
incing responses to an allogeneic GVL effect.
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5LBCL and B-Cell LBL
In contrast to small-cell lymphoma, DLBCL and
-cell LBL express signiﬁcantly less CD86 [77] and
emonstrate MHC class I downregulation in both
nimal models [85] and clinical samples [86] of B-cell
LCL. These biological features of large-cell lym-
homas lead to failure of recognition by CTLs and
ikely escape from immune attack. There may, how-
ver, not be uniformity in the apparent inability of
-cell DLCL to induce T-cell activation. Lympho-
hip technology has demonstrated that B-cell DLCL
an be separated on the basis of gene expression into
ither a normal germinal center phenotype or an ac-
ivated peripheral blood B-cell phenotype [87,88]. Al-
hough the latter group shows a poorer prognosis
hen treated with conventional chemotherapy, these
enotypic differences may indicate a greater ability to
nitiate a cytotoxic response by allogeneic T cells.
his is countered by the ﬁnding that the antiapoptotic
enes PDCE4B and PKC are overexpressed in these
ubgroups. Clinical studies are required to clarify the
ffect of genotypic differences on susceptibility to
VL effects.
TL Trafficking
To take advantage of the potential APC function
f B cells, T cells must ﬁrst gain access to the sites of
ymphoma involvement. Although naive T cells can
reely access the secondary lymphoid tissues, activated
TLs are excluded from doing so by the downregu-
ation of the chemokine receptor CCR7 [89]. As a
onsequence, T cells activated by exposure to alloan-
igens expressed on APCs outside of the lymph nodes,
uch as DCs resident within epithelial tissues, are
ctively excluded from “seeing” residual lymphoma
ells within a lymph node. Thus, for a GVL effect to
ccur, both the activation and effector phases of the
VL effect must occur within the lymphomatous
ode, as occurs in the lymphoid hypoplasia associated
ith GVHD [90]. T-cell trafﬁcking to sites of lym-
homatous involvement may also vary between lym-
homa subtypes. For example, CLL B cells actively
ttract CD4 T-cell help via the expression of che-
okine ligand 22 [91]. The implication of these vari-
tions in T-cell trafﬁcking is that after allogeneic
MT, residual CLL may actively recruit allogeneic T
ells and be activated into APC function, as outlined
reviously.
The requirement for both activation and effector
esponses to occur within the lymph node may limit
he application of adoptive transfer of ex vivo–acti-
ated CTLs and may necessitate in vivo CTL gener-
tion either by allogeneic transplantation or vaccina-
ion strategies. To this end, manipulation of
llogeneic T-cell trafﬁcking by using the sphingosine-
-phosphate receptor agonist FTY720, which traps p
86llogeneic T cells within the secondary lymphoid tis-
ues, has been used to promote a GVL effect while
reventing the development of GVHD in the periph-
ral tissues in a haploidentical mouse model [92]. This
gent has not, however, been successful in treating
stablished GVHD in a nonidentical canine model
93]. The differences in outcome observed between
hese models likely reﬂect the fundamental differences
etween preventing the onset of GVHD and attempt-
ng to suppress activated circulating T cells.
-Cell Lymphoma
The ability of T lymphoma cells to function as
PCs in the activation of antilymphoma CTLs is less
ell described than for B cells. Normal T cells express
HC class I and, when activated, high levels of MHC
lass II in addition to low levels of co-stimulatory
olecules. In vitro studies demonstrate that T cells
ay also be targeted by CTL clones [94]. Low-grade
utaneous T-cell lymphomas express high levels of
HC class II, which initiate allogeneic cytotoxicity
ufﬁcient to eradicate the lymphoma [95].
UTURE DIRECTIONS
The challenges faced in the application of alloge-
eic SCT to the treatment of lymphomas center on
imiting GVHD and identifying those subtypes of
ymphoma that are sensitive to CTL-mediated cyto-
oxicity. It is likely that the B-cell malignancies that
re genotypically or phenotypically similar to normal
cells able to differentiate into an effective APC
henotype, sensitive to apoptosis induction and per-
issive to T-cell trafﬁcking, will be more sensitive to
VL effects. Whether genotype analyses with mi-
roarray technology can help in identifying immuno-
esponsive lymphoma subgroups is unknown.
To date, lymphoma-speciﬁc antigenic targets for
he GVL effect remain limited; hence, it is not yet
ossible to achieve adoptive immunotherapy with
ighly selected, ex vivo–expanded GVL-speciﬁc
TLs. As a result, means of controlling allogeneic
-cell function are the current focus of research. It
as been suggested that delaying T-cell infusions until
fter resolution of the cytokine storm may maintain
he antitumor efﬁcacy of engrafted T cells while lim-
ting nonspeciﬁc alloreactivity. This is an attractive
ypothesis and has been effectively demonstrated in
nimal models [96,97], but it is hindered by the dual
bservations that maximal GVL effect is dependent
n a state of mixed APC chimerism and that predic-
ion of GVHD risk at any given dose of DLI is
mprecise [98]. Given the difﬁculties of minimizing
VHD by manipulating T-cell doses or timing, there
as been increased interest in the use of regulatory cell
opulations to restrict the action of allogeneic CTLs.
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Both regulatory T cells [99] and regulatory DCs [100]
re capable of limiting GVHD while preserving the
VL effect. These phenomena are yet to be tested in
he clinical setting.
Given the central role of host APCs in the induc-
ion of GVL after SCT, vaccination with either au-
ologous DCs or irradiated, ex vivo–activated lym-
homa cells may lead to enhanced re-stimulation of
ngrafted allogeneic T-cell responses against minimal
esidual disease and result in lower rates of recurrence.
ouse models of pretransplantation vaccination of
onors [101-103] and posttransplantation vaccination
104,105] of recipients have been shown to result in
nhanced graft-versus-tumor effects without exacer-
ation of GVHD. These strategies have not yet been
emonstrated in a clinical setting, but they offer great
otential in the delivery of enhanced immunotherapy
s an adjunct to allogeneic SCT.
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